Invokana Dosage

Generic name: CANAGLIFLOZIN 100mg
Dosage form: tablet, film coated
Drug class: SGLT-2 inhibitors

Medically reviewed by Drugs.com. Last updated on Oct 22, 2024.

Prior to Initiation of INVOKANA

Assess renal function before initiating INVOKANA and as clinically indicated .

In patients with volume depletion, correct this condition before initiating INVOKANA .

Recommended Dosage and Administration

•: The recommended dosage of INVOKANA is 100 mg orally once daily, taken before the first meal of the day.
•: For additional glycemic control, the dosage of INVOKANA may be increased to the maximum recommended dosage of 300 mg once daily.

Recommended Dosage in Patients with Renal Impairment

Table 1 provides dosage recommendations for patients with renal impairment, based on estimated glomerular filtration rate (eGFR).

Table 1: Recommended Dosage in Patients with Renal Impairment
Estimated Glomerular Filtration Rate [eGFR (mL/min/1.73 m 2)]	Recommended Dosage
eGFR 30 to less than 60	The maximum recommended dosage is 100 mg orally once daily.
eGFR less than 30	• Initiation is not recommended • Patients taking INVOKANA with albuminuria greater than 300 mg/day may continue INVOKANA 100 mg once daily to reduce the risk of ESKD, doubling of serum creatinine, CV death, and hospitalization for heart failure.

Concomitant Use with UDP-Glucuronosyl transferase (UGT) Enzyme Inducers

When co-administering INVOKANA with an inducer of UGT (e.g., rifampin, phenytoin, phenobarbital, ritonavir), increase the dosage of INVOKANA based on renal function:

•: In patients with eGFR 60 mL/min/1.73 m 2or greater, increase the dosage to 200 mg orally once daily in patients currently tolerating INVOKANA 100 mg once daily. The maximum recommended dosage of INVOKANA is 300 mg once daily.
•: In patients with eGFR less than 60 mL/min/1.73 m 2, increase to a maximum recommended dosage of 200 mg orally once daily in patients currently tolerating INVOKANA 100 mg once daily.

Temporary Interruption for Surgery

Withhold INVOKANA at least 3 days, if possible, prior to surgery or procedures associated with prolonged fasting. Resume INVOKANA when the patient is clinically stable and has resumed oral intake.